Cantaloupe Inc (CTLP) Q3 2025 Earnings Call Highlights: Revenue Growth and Smart Store Success ...
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Cantaloupe Inc (NASDAQ:CTLP) reported an 11% year-over-year increase in total revenue for Q3 2025, reaching $75.4 million.
The company achieved a 37% increase in adjusted EBITDA, amounting to $13.9 million, reflecting successful margin expansion and operating leverage.
Cantaloupe Inc (NASDAQ:CTLP) experienced strong cash generation, with $22.4 million in cash from operating activities during the quarter.
The company saw significant growth in its smart store product, with over $2 million in shipments, indicating strong demand in new verticals.
Cantaloupe Inc (NASDAQ:CTLP) released a $42.2 million valuation allowance on deferred tax assets, contributing to a net income of $48.9 million for the quarter.
Revenue was lower than anticipated due to one-time weather events impacting transaction revenue and delays in equipment purchases.
Transaction revenue was materially impacted by adverse weather events, leading to abnormally low traffic in customer locations.
There was a pullback in large equipment purchases due to economic uncertainty, affecting sales in the quarter.
The company faced supply constraints for its smart store product, limiting its ability to meet demand.
International revenue remains a small portion of total revenue, expected to be only 3-4% by the end of fiscal year 2025.
Warning! GuruFocus has detected 3 Warning Signs with CTLP.
Q: Can you quantify the weather impact on transaction revenue for the quarter? A: Yes, the weather impact was approximately $2 million, mostly in January and a little in February. - Scott Stewart, CFO
Q: What are the early indications of demand for the smart store product, and do you expect it to ramp up quickly? A: We are already seeing a ramp-up in the fourth quarter. The smart store is our hottest selling product, with significant interest at industry conferences. We expect it to translate into strong fourth-quarter equipment revenue. - Ravi Venkates, CEO
Q: Can you provide updates on your progress in Europe and Latin America? A: We have exciting updates, but it's premature to share them. Scaling is continuing with large customers and in the SMB space. Expect releases soon. - Ravi Venkates, CEO
Q: How does the revenue opportunity compare between traditional vending, smart stores, and other verticals? A: Vending will grow 5-6%, micro markets 30-40%, and smart stores and related technologies could grow 100-200% in the next 2-3 years, becoming a significant market share. - Ravi Venkates, CEO
Q: What do you expect international revenue to be as a percentage by the end of the year? A: We anticipate international revenue to be 3-4% as we exit the fourth quarter of fiscal year 2025, with continued growth expected in FY26. - Scott Stewart, CFO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment
Zai Lab Ltd (NASDAQ:ZLAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On June 30, Leerink Partners raised its price target for the stock to $75 from $73. The research firm also reiterated an 'Outperform' rating on the stock. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. The research firm hiked its price target following positive Phase III trial results from the FORTITUDE-101 study. The study was evaluating bemarituzumab as a first-line FGFR2B-positive gastric cancer treatment. The candidate drug, developed in partnership with Amgen, met its primary endpoint while demonstrating a significant and clinically meaningful overall survival benefit compared to placebo plus chemotherapy. Following the positive results, Zai Labs plans a second Phase III trial, FORTITUDE-102, which will evaluate bemarituzumab in combination with chemotherapy and nivolumab. The company expects top-line data in the second half of the year that will affirm the candidate drug as a first-line treatment for gastric cancer. It also plans to file for regulatory approval in China following the positive results. Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. While we acknowledge the potential of ZLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a 'Neutral' rating on the stock and increased its price target to $62 from $61. A pharmacist preparing a dose of an immuno-oncology agent for research use. The price hike comes as UBS expects higher sales for Incyte's Niktimvo, a treatment for chronic Graft-versus-Host Disease (cGVHD). Amid the expected higher sales, UBS has revised its 2026 earnings per share estimate of $6.36 from $6.26. UBS also maintained a 9.5x price-to-earnings multiple on Incyte, as it expects the company's second-quarter earnings call to provide clarity on the company's strategic direction. The company's pipeline has already received a boost following the FDA's extension of the review for ruxolitinib cream for pediatric atopic dermatitis. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in oncology and inflammation & autoimmunity. It also boasts a growing portfolio of treatments for other diseases, including those in dermatology. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22 minutes ago
- Yahoo
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
Genmab A/S (NASDAQ:GMAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 8, Truist Securities reiterated a 'Buy' rating on the stock and increased its price target to $46 from $45. A doctor in a hospital consulting with a cancer patient about immuno-oncology therapy. According to Truist Securities, the current valuation does not depict the company's fair value. That's because it boasts an established revenue and solid pipeline potential. The price target adjustment underscores Truist Securities' confidence about Genmab's revenue outlook for 2025. The research firm is confident about the company's cancer drug Darzalex as prescription data indicates 10% quarter-over-quarter growth in Q2. The firm is also bullish about the company's other products, including Epkinly and Kesimpta. Truist Securities has also expressed confidence in Genmab's pipeline assets, including Rina-S, Acasun, and Gen1042, which it believes are undervalued. Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. It utilizes advanced antibody technologies, such as DuoBody and HexaBody, to create next-generation therapeutic antibodies. While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
